The Latest Breaking News from Doug Drysdale

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock.  In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy. 

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you.

CYB004 is one of Cybin’s (NYSE:CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and substance abuse disorders. According to the company, the substance has recently shown positive preclinical data over DMT, the molecule from which it is derived. Cybin has observed that the preclinical study showed promising results for…

Cybin Inc. (NYSE:CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods for psychedelic molecules. “Our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation,…

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE:CYBN) CEO, Doug Drysdale has certainly had an eventful career. “I seem to be drawn to opportunities that are poised for growth, whether that is from being undermanaged, distressed or a startup situation,” he said in an interview, explaining his…

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway,  announced Cybin Inc. (NYSE:CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without the need for a more expensive and oversized piece of equipment, Kernal Flow…

Cybin Inc. (NYSE:CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. The goal is to analyze the potential of the compound in treating major depressive disorder (MDD). The studies were carried out on multiple species and included several doses of the substance, which were reportedly…